Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Kiora Pharmaceuticals
KIO-104 is an ophthalmic formulation for intravitreal injection of KIO-100, a non-steroidal small molecule that inhibits dihydroorotate dehydrogenase (DHODH). It is being studied in macular edema.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06825702 | Phase 2 | Macular Edema | Recruiting | KPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Macular Edema
Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.
See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPRX catalysts and pipeline →